OBJECTIVE: To evaluate the outcome of women with hypogonadotropic hypogonadism (HH) undergoing in-vitro fertilization (IVF). MATERIALS AND METHODS: Data from 13 cycles often hypogonadotropic patients treated with in vitro fertilization from the period January 2006 to January 2008 were analyzed and compared with treatment results from 20 patients with tubal factor infertility (TI). All patients underwent ovarian hyperstimulation for IVF/ICSI at the same center. HH patients initiated the treatment by receiving daily injections of hMG. The patients in the control group were given the same dosage of recombinant FSH. RESULTS: Demographic characteristics of the patients were comparable. Mean duration of stimulation was 13 days in the HH group and nine days in the TI group; the difference was significant (p < 0.001). Significantly more gonadotropins were used for the stimulation of HH patients (p < 0.05). Peak serum E2 concentration was found to be higher in the TI group. We evaluated the proportion of metaphase II (MII) oocytes to total oocytes retrieved in HH patients and found the number was similar to the TI group. Despite that fertilization and implantation rates were similar in both groups, the cancellation rate was higher in the HH group (23.1% vs 0). However pregnancy and live birth rates were similar. CONCLUSIONS: The present study showed that HH women undergoing IVF/ICSI are good responders. The treatment of HH women with IVF/ICSI did not increase multiple pregnancies and OHSS rates over the TI group.
OBJECTIVE: To evaluate the outcome of women with hypogonadotropic hypogonadism (HH) undergoing in-vitro fertilization (IVF). MATERIALS AND METHODS: Data from 13 cycles often hypogonadotropic patients treated with in vitro fertilization from the period January 2006 to January 2008 were analyzed and compared with treatment results from 20 patients with tubal factor infertility (TI). All patients underwent ovarian hyperstimulation for IVF/ICSI at the same center. HHpatients initiated the treatment by receiving daily injections of hMG. The patients in the control group were given the same dosage of recombinant FSH. RESULTS: Demographic characteristics of the patients were comparable. Mean duration of stimulation was 13 days in the HH group and nine days in the TI group; the difference was significant (p < 0.001). Significantly more gonadotropins were used for the stimulation of HHpatients (p < 0.05). Peak serum E2 concentration was found to be higher in the TI group. We evaluated the proportion of metaphase II (MII) oocytes to total oocytes retrieved in HHpatients and found the number was similar to the TI group. Despite that fertilization and implantation rates were similar in both groups, the cancellation rate was higher in the HH group (23.1% vs 0). However pregnancy and live birth rates were similar. CONCLUSIONS: The present study showed that HHwomen undergoing IVF/ICSI are good responders. The treatment of HHwomen with IVF/ICSI did not increase multiple pregnancies and OHSS rates over the TI group.
Authors: Gustavo N Cecchino; Guillermo M Canillas; María Cruz; Juan A García-Velasco Journal: J Assist Reprod Genet Date: 2019-10-18 Impact factor: 3.412